Marker Therapeutics, Inc.

Tagged: clinical update

Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.

Read More

TapImmune CEO Provides Update on Corporate Activity and Progression of Clinical Programs

…I am pleased to provide this update to existing shareholders and interested potential shareholders

SEATTLE–(BUSINESS WIRE)–

TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease. The company now has multiple clinical trials underway at the Mayo Clinic in Rochester, MN, as well as an infectious disease program also completing pre-clinical testing at Mayo for a novel smallpox vaccine.

Read More